Kazia Therapeutics Limited
Every calculator, already run for KZIA
Open the full toolkit →You have the numbers on KZIA. Get the argument.
A written report on which of these readings actually decide the outcome for Kazia Therapeutics Limited, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
6 analysts covering KZIAAnalyst Price Target Disagreement for Kazia Therapeutics Limited
Wall Street's bull case implies +309% from the current price; the bear case implies +82%. A 227% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for KZIA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Kazia Therapeutics Limited
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It als…
KZIA — frequently asked
Is KZIA a buy right now?
Wall Street's consensus rating on Kazia Therapeutics Limited is Strong Buy across 6 analysts, with a mean price target of $28.39 (+196% vs. the current $9.60). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is KZIA overvalued?
KZIA trades at — trailing earnings, against a DCF fair value of $1 per share. The current price implies 41% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
What is the analyst price target disagreement for Kazia Therapeutics Limited?
Analysts covering Kazia Therapeutics Limited (KZIA) range from a bear-case target of $17.51 to a bull-case high of $39.27, with a mean consensus target of $28.39 across 6 analysts. The spread of $21.76 (227% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Kazia Therapeutics Limited against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Kazia Therapeutics Limited
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full KZIA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Kazia Therapeutics Limited, in minutes. 3 free reports included with every account — no credit card required.